Canvas Wealth Advisors’s Biogen BIIB Stock Holding History

Canvas Wealth Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-762	Closed	-$214K	–	146
2022 Q3	$214K	Buy	+762	New	+$162K	0.09%	116
2022 Q1	–	Sell	-850	Closed	-$204K	–	146
2021 Q4	$204K	Buy	850 +73	+9%	+$18.8K	0.07%	130
2021 Q3	$220K	Buy	777 +8	+1%	+$2.62K	0.09%	111
2021 Q2	$266K	Buy	+769	New	+$233K	0.12%	102

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Canvas Wealth Advisors's BIIB Position: Q4 2022 in Review

Canvas Wealth Advisors sold out of Biogen (BIIB) in Q4 2022, closing a stake of 762 shares — an estimated $214K sold.

Canvas Wealth Advisors first reported a position in BIIB in Q2 2021 and held it in 4 quarters. The position peaked at $266K in Q2 2021. 1,031 funds tracked by Wall St. Rank hold BIIB as of Q4 2022.

Canvas Wealth Advisors reported no remaining Biogen position as of Q4 2022 after selling out during the quarter.
Canvas Wealth Advisors sold 762 Biogen shares in Q4 2022, an estimated $214K.
Canvas Wealth Advisors first reported a position in Biogen in Q2 2021 and held it in 4 quarters.
Canvas Wealth Advisors's Biogen position peaked at $266K in Q2 2021.
1,031 funds tracked by Wall St. Rank held Biogen as of Q4 2022.

Based on Canvas Wealth Advisors's 13F filing for Q4 2022, filed 23 Jan 2023.